TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17010507

Group type: EXPERIMENTAL
Intervention: Retropubic route (RPR)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Transobturator route (TOR)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both RPR and TOR
Number of subjects: 88
Study: 16269589

Group type: COMPARATOR
Intervention: Desipramine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD+OH group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAF group
Number of subjects: 0
Study: 12043306

Group type: EXPERIMENTAL
Intervention: Moraxella catarrhalis isolated in patients with bronchial asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial flora of the upper respiratory tract in patients with bronchial asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candida isolation in asthmatics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bronchial tree secretion as diagnostic material
Number of subjects: 0
Study: 10541326

Group type: EXPERIMENTAL
Intervention: Gestational mammary gland specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammatory specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactating adenoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gynecomastia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal resting breast
Number of subjects: 0
Study: 7596933

Group type: EXPERIMENTAL
Intervention: Fluconazole, 400 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 70
Study: 2351027

Group type: EXPERIMENTAL
Intervention: Self-management training (SMT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 36

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 36
Study: 484644

Group type: EXPERIMENTAL
Intervention: Anaprox (1,100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30068215

Group type: EXPERIMENTAL
Intervention: Walnut inclusion (56 g of walnuts daily for 6 months)
Number of subjects: 112
Study: 28441618

Group type: EXPERIMENTAL
Intervention: Substance use (alcohol and illicit drugs)
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: High levels of motivation
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Substance using patients
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Any substance, alcohol, and cannabis use
Number of subjects: 1434
Study: 26545912

Group type: EXPERIMENTAL
Intervention: SMART intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 58
Study: 25380344

Group type: EXPERIMENTAL
Intervention: 2% typified propolis rinse
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.05% sodium fluoride plus 0.05% cetylpyridinium chloride rinse (positive control)
Number of subjects: 42
Study: 22540330

Group type: EXPERIMENTAL
Intervention: STICA treatment (manualized short-term treatment of IA/CA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study: 19944393

Group type: EXPERIMENTAL
Intervention: Left atrial radiofrequency ablation (RFA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Valvular surgery alone (Control)
Number of subjects: 43
Study: 17659455

Group type: EXPERIMENTAL
Intervention: Nutrition MCT enteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutrition MF enteral nutrition
Number of subjects: 0
Study: 16481908

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg bw)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg bw)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.2 mmol/kg bw)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.2 mmol/kg bw)
Number of subjects: 12
Study: 12216561

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement 2
Number of subjects: 0
Study: 9700889

Group type: EXPERIMENTAL
Intervention: Bifidumbacterin and carbolen
Number of subjects: 0
Study: 7638220

Group type: EXPERIMENTAL
Intervention: Paired training session
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control session (unpaired presentations)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paired test session
Number of subjects: 12
Study: 2677410

Group type: EXPERIMENTAL
Intervention: Terodiline
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 343006

Group type: EXPERIMENTAL
Intervention: 1 mg prazosin
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5 mg prazosin
Number of subjects: 24
Study: 31301668

Group type: EXPERIMENTAL
Intervention: IVT ranibizumab (3 injections 0.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVT ranibizumab (1 injection 0.5 mg) + LP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone IVT implant (0.7 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone IVT implant (0.7 mg) + LP
Number of subjects: 60
Study: 28169458

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF) + home pelvic floor muscle training (PFMT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Biofeedback (BF) and Pelvic floor muscle training (PFMT)
Number of subjects: 72
Study: 25456098

Group type: COMPARATOR
Intervention: T2DM patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: FCH patients
Number of subjects: 51
Study: 23568174

Group type: EXPERIMENTAL
Intervention: Formulation M + OPV placebo
Number of subjects: 446

Group type: COMPARATOR
Intervention: DTaP + OPV
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: All formulations of DTaP-sIPV
Number of subjects: 446
Study: 21751165

Group type: EXPERIMENTAL
Intervention: Lithium carbonate pre-treatment (1.0 g/day for 6 days before and 3 days after radioiodine therapy)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lithium carbonate pre-treatment
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with lithium carbonate pre-treatment
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no lithium treatment)
Number of subjects: 128
Study: 19847599

Group type: EXPERIMENTAL
Intervention: FGLM‐amide and SSSR eyedrops (n = 14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Phosphate-buffered saline eyedrops (n = 15)
Number of subjects: 29
Study: 16424409

Group type: EXPERIMENTAL
Intervention: Salmeterol, 42 mug bid via metered-dose inhaler (MDI)
Number of subjects: 26355

Group type: COMPARATOR
Intervention: Placebo bid via metered-dose inhaler (MDI)
Number of subjects: 26355
Study: 15274385

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2 plus docetaxel 90 mg/m2 every 3 weeks with prophylactic G‐CSF
Number of subjects: 25
Study: 14517197

Group type: EXPERIMENTAL
Intervention: Diltiazem HCl ER tablets administered in the evening (360 mg single-dose and multiple-dose for 7 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diltiazem HCl ER tablets administered in the evening (360 mg once daily for 7 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diltiazem HCl ER tablets administered in the evening
Number of subjects: 48
Study: 10200003

Group type: EXPERIMENTAL
Intervention: LEV 0.1 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LEV 0.2 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LEV 0.4 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7497198

Group type: EXPERIMENTAL
Intervention: Care in a stroke unit
Number of subjects: 10
Study: 2156368

Group type: EXPERIMENTAL
Intervention: Diet with unprocessed wheat bran (30 g of dietary fiber)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diet with unprocessed wheat bran
Number of subjects: 17
Study: 6932064

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo elixir
Number of subjects: 10
Study: 30799019

Group type: EXPERIMENTAL
Intervention: Mobile app (Transplant Hero) and smart watch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mobile app (Transplant Hero) only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither app nor smart watch
Number of subjects: 0
Study: 28902533

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1538
Study: 25805187

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg + low-dose metformin (1000 mg)
Number of subjects: 689

Group type: COMPARATOR
Intervention: High-dose metformin (2000 mg)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Linagliptin + low-dose metformin (1000 mg)
Number of subjects: 689
Study: 23856559

Group type: EXPERIMENTAL
Intervention: Dronabinol (maximum dose 28 mg per day, titrated against bodyweight and adverse effects)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 21855689

Group type: EXPERIMENTAL
Intervention: Multi-factor ergonomic intervention program
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Non-randomized control group
Number of subjects: 1480
Study: 19895777

Group type: COMPARATOR
Intervention: Assessment (n = 152)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Intervention (n = 147)
Number of subjects: 446
Study: 17470688

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy with a platinum-based doublet followed by a single agent.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential single agents.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternating chemotherapy strategy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidation/maintenance chemotherapy.
Number of subjects: 0
Study: 15104322

Group type: EXPERIMENTAL
Intervention: Thermoluminescent dosemeters (TLD) used to assess operators' extremity doses during procedures
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preliminary occupational dose constraint value calculated from cardiologists' annual effective dose
Number of subjects: 40
Study: 11279290

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Canavan disease group
Number of subjects: 2
Study: 9041570

Group type: EXPERIMENTAL
Intervention: Thiopentone/Isolfurane anaesthetic
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol anaesthetic
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 22
Study: 7947876

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intracoronary ultrasonography
Number of subjects: 51

Group type: COMPARATOR
Intervention: Coronary angiography
Number of subjects: 51
Study: 29885911

Group type: EXPERIMENTAL
Intervention: Intra-articular Botulinum toxin injections (30 units)
Number of subjects: 77
Study: 27725121

Group type: EXPERIMENTAL
Intervention: Endurance exercise (30 minutes of bicycling)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (22 sessions)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Endurance exercise (acute and prolonged)
Number of subjects: 42
Study: 24638241

Group type: EXPERIMENTAL
Intervention: 0.5 Gy
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 1.0 Gy
Number of subjects: 312
Study: 21979803

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with an inspiratory load of 50% of maximal inspiratory pressure (Pi(max))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CON) with an inspiratory load of 15% of maximal inspiratory pressure (Pi(max))
Number of subjects: 16
Study: 20203321

Group type: EXPERIMENTAL
Intervention: High NMES (60 minutes per day for 4 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low NMES (30 minutes per day for 4 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no NMES)
Number of subjects: 66
Study: 19065894

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d) and Bailing Capsule (2.0 g, twice a day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bailing Capsule alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Immunosuppressive agents (control)
Number of subjects: 84
Study: 16648320

Group type: EXPERIMENTAL
Intervention: 10,000-lux light treatment and placebo capsule
Number of subjects: 96

Group type: COMPARATOR
Intervention: 100-lux light treatment (placebo light) and fluoxetine, 20 mg/day
Number of subjects: 96
Study: 12795792

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 504
Study: 10994615

Group type: EXPERIMENTAL
Intervention: H. pylori IgG serology negative in patients aged 45 years or less
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Serum pepsinogen I levels
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Combination of serum pepsinogen I assay and H. pylori IgG serology
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Normal IgG serology and serum pepsinogen I
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Normal blood tests
Number of subjects: 207
Study: 9011452

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment (13-15 mg/kg/day for >3 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated cholestatic patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (14 healthy volunteers)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: UDCA treatment (38+/‐8 months)
Number of subjects: 27
Study: 1601765

Group type: EXPERIMENTAL
Intervention: Cefpirome
Number of subjects: 897

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 897
Study: 2869470

Group type: EXPERIMENTAL
Intervention: 15 mg clorazepate dipotassium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29974811

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 36 hours of fasting
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Three days of a hypercaloric high‐fat diet
Number of subjects: 9
Study: 29570501

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 12 mL/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 60 mL/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 300 mL/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 600 mL/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at injection speed of 1800 mL/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 26697890

Group type: EXPERIMENTAL
Intervention: Mildronate injection 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mildronate injection 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mildronate injection 750 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-dose mildronate administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall safety and tolerability of mildronate
Number of subjects: 0
Study: 24608017

Group type: EXPERIMENTAL
Intervention: Abstainers (n = 92)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Intermittent smokers (n = 49)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Persistent smokers (n = 38)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 179
Study: 22658758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4073

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels at baseline
Number of subjects: 4073

Group type: EXPERIMENTAL
Intervention: Normal baseline testosterone (≥10 nmol/l)
Number of subjects: 4073

Group type: EXPERIMENTAL
Intervention: DHT levels
Number of subjects: 4073
Study: 19369866

Group type: EXPERIMENTAL
Intervention: Oral glycerol (GLY)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) and Oral glycerol (GLY)
Number of subjects: 654
Study: 17683328

Group type: EXPERIMENTAL
Intervention: 20 mg of hydroxyzine (Atarax) 24 h preoperatively and 3.7 mg/kg hydroxyzine orally on the operation day
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3.7 mg/kg hydroxyzine orally only on the operation day
Number of subjects: 30
Study: 15737255

Group type: EXPERIMENTAL
Intervention: Arthrodesis of first MTP joint
Number of subjects: 31

Group type: COMPARATOR
Intervention: Mayo resection
Number of subjects: 31
Study: 12196363

Group type: COMPARATOR
Intervention: Tamoxifen (TAM group)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus chemotherapy (TAM-CT group)
Number of subjects: 835
Study: 9794557

Group type: EXPERIMENTAL
Intervention: Kimmelstiel Wilson nodules
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mesangial sclerosis lesions
Number of subjects: 36
Study: 7649959

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at doses of 0.3, 0.6, 0.9 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2564785

Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 45

Group type: COMPARATOR
Intervention: vecuronium or pancuronium
Number of subjects: 45
Study: 326385

Group type: EXPERIMENTAL
Intervention: Combined hormone and polychemotherapy (oophorectomy plus modified five-drug 'Cooper' combination)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Combined hormone and polychemotherapy (diethylstilbestrol and cytostatic therapy)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus progesterone
Number of subjects: 213

Group type: COMPARATOR
Intervention: Polychemotherapy alone (control group)
Number of subjects: 213
Study: 30394240

Group type: EXPERIMENTAL
Intervention: Reduction of CRP level during the initial follow-up interval (T1-T2)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Change in CRP level
Number of subjects: 208
Study: 29237420

Group type: EXPERIMENTAL
Intervention: Text and voice messages containing information and encouragement to undergo screening
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 400
Study: 26505681

Group type: EXPERIMENTAL
Intervention: XELIRI/FOLFIRI plus simvastatin (40 mg)
Number of subjects: 269

Group type: COMPARATOR
Intervention: XELIRI/FOLFIRI plus placebo
Number of subjects: 269
Study: 23411675

Group type: EXPERIMENTAL
Intervention: Variable task with graded instability, practiced for about 1 hour.
Number of subjects: 0
Study: 21323568

Group type: EXPERIMENTAL
Intervention: docetaxel plus imatinib
Number of subjects: 88

Group type: COMPARATOR
Intervention: docetaxel alone
Number of subjects: 88
Study: 19762758

Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 91
Study: 17827829

Group type: EXPERIMENTAL
Intervention: Telmisartan (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan (40 mg/day)
Number of subjects: 0
Study: 15214905

Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 8 weeks followed by calcipotriol ointment once daily for 4 weeks
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 4 weeks followed by calcipotriol ointment once daily on weekdays and the two-compound product once daily at weekends
Number of subjects: 972

Group type: COMPARATOR
Intervention: Calcipotriol ointment twice daily for 12 weeks
Number of subjects: 972
Study: 11816704

Group type: EXPERIMENTAL
Intervention: Mesoglycan 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally for 20 weeks
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 242
Study: 9522105

Group type: EXPERIMENTAL
Intervention: Cefaclor 25 mg/kg BID
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate 15 mg/kg TID
Number of subjects: 245

Group type: COMPARATOR
Intervention: Erythromycin 15 mg/kg TID
Number of subjects: 245
Study: 8025984

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2508608

Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg/d
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Tocopherol (vitamin E) 2000 IU/d
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg/d and Tocopherol (vitamin E) 2000 IU/d
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 324773

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150‐200 mg daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (300‐400 mg daily)
Number of subjects: 27
Study: 29313271

Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP) in addition to DMARDs (leflunomide and methotrexate)
Number of subjects: 72

Group type: COMPARATOR
Intervention: DMARDs (leflunomide and methotrexate)
Number of subjects: 72
Study: 27459586

Group type: EXPERIMENTAL
Intervention: Androgen receptor inhibitor monotherapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Castration plus an androgen receptor inhibitor
Number of subjects: 110
Study: 24595146

Group type: COMPARATOR
Intervention: 40 mg lidocaine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 80 mg lidocaine
Number of subjects: 68
Study: 22459918

Group type: EXPERIMENTAL
Intervention: Dienogest (DNG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide acetate (LA)
Number of subjects: 0
Study: 20117379

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin + omega-3 fatty acids (4 capsules daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin 325 mg daily
Number of subjects: 30